

KERYX BIOPHARMACEUTICALS INC
Form 8-K
August 03, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 3, 2004

KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

DELAWARE	000-30929	13-4087132
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)

=====

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 3, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press release announcing results of operations for the second quarter ended June 30, 2004. Keryx also announced that it would host a conference call on August 5, 2004, for investors where Keryx will discuss its results of operations and financial results, as well as the clinical programs for certain of its drug candidates. A copy of such press release is being furnished as Exhibit 99.1 to this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KERYX BIOPHARMACEUTICALS, INC.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

(Registrant)

Date: August 3, 2004

By: /s/ Ron Bentsur

Ron Bentsur
Vice President Finance and
Investor Relations

INDEX TO EXHIBITS

EXHIBIT
NUMBER

DESCRIPTION

99.1

Press Release dated August 3, 2004.